D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $34.00 price objective on the stock. NRXP has been the subject of a number of other research reports. HC Wainwright restated [...]